MS 8209

Drug Profile

MS 8209

Latest Information Update: 13 Nov 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Mayoly-Spindler
  • Class Antifungals; Antivirals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Creutzfeldt-Jakob disease; HIV infections; Mycoses

Most Recent Events

  • 10 Feb 2000 A preclinical study has been added to the Viral infections pharmacodynamics section
  • 12 May 1999 Preclinical development for Mycoses in France (Unknown route)
  • 08 Sep 1997 A preclinical study has been added to the pharmacokinetics and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top